Global Asthma and COPD Drug Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Asthma and COPD Drug Market Insights, Forecast to 2034
Asthma and chronic obstructive pulmonary disease (COPD) drugs are medications used to manage and treat respiratory conditions.
Global Asthma and COPD Drug market is expected to reach to US$ 13270 million in 2024, with a positive growth of %, compared with US$ 12560 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Asthma and COPD Drug industry is evaluated to reach US$ 15210 million in 2029. The CAGR will be 2.3% during 2024 to 2029.
The market for asthma and COPD drugs is driven by the high prevalence of respiratory diseases and the increasing demand for effective and personalized treatments. The growing awareness of respiratory health and the development of novel therapeutics further boost the market growth.
Report Covers
This report presents an overview of global Asthma and COPD Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Asthma and COPD Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Boehringer Ingelheim
GlaxoSmithKline
Merck and Co
Novartis AG
AstraZeneca
F. Hoffmann-La Roche
Segment by Type
Bronchodilators
Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
Asthma
COPD
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Asthma and COPD Drug plant distribution, commercial date of Asthma and COPD Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Asthma and COPD Drug introduction, etc. Asthma and COPD Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Asthma and COPD Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Asthma and COPD Drug market is expected to reach to US$ 13270 million in 2024, with a positive growth of %, compared with US$ 12560 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Asthma and COPD Drug industry is evaluated to reach US$ 15210 million in 2029. The CAGR will be 2.3% during 2024 to 2029.
The market for asthma and COPD drugs is driven by the high prevalence of respiratory diseases and the increasing demand for effective and personalized treatments. The growing awareness of respiratory health and the development of novel therapeutics further boost the market growth.
Report Covers
This report presents an overview of global Asthma and COPD Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Asthma and COPD Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Boehringer Ingelheim
GlaxoSmithKline
Merck and Co
Novartis AG
AstraZeneca
F. Hoffmann-La Roche
Segment by Type
Bronchodilators
Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
Segment by Application
Asthma
COPD
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Asthma and COPD Drug plant distribution, commercial date of Asthma and COPD Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Asthma and COPD Drug introduction, etc. Asthma and COPD Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Asthma and COPD Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports